Dashboard
Manage Tickers

IPSCCentury Therapeutics, Inc.

Nasdaq centurytx.com


$ 3.13 $ -0.13 (-3.99 %)    

Friday, 14-Jun-2024 15:59:13 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 3.13
$ 3.26
$ 0.00 x 0
$ 0.00 x 0
$ 3.10 - $ 3.26
$ 1.28 - $ 5.51
110,931
na
259.31M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

5-analysts-assess-century-therapeutics-what-you-need-to-know
5 Analysts Assess Century Therapeutics: Wh...
06/04/2024 15:00:14

hc-wainwright--co-reiterates-buy-on-century-therapeutics-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Cent...
06/04/2024 10:36:57

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Century Therapeutics (NASDAQ:IPSC) with a Buy and maintains $11 p...

century-therapeutics-presents-interim-results-from-phase-1-elipse-1-study-of-cnty-101-at-asco-2024-annual-meeting-in-patients-with-relapsed-or-refractory-cd19-positive-b-cell-malignancies
Century Therapeutics Presents Interim Resu...
06/03/2024 11:08:49

In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majo...

hc-wainwright--co-maintains-buy-on-century-therapeutics-lowers-price-target-to-11
HC Wainwright & Co. Maintains Buy on Centu...
05/10/2024 11:45:07

HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price...

century-therapeutics-presents-preclinical-data-highlighting-advances-in-ipsc-platform-technology-and-programs-at-2024-asgct-annual-meeting
Century Therapeutics Presents Preclinical ...
05/10/2024 11:23:00

century-therapeutics-q1-2024-gaap-eps-045-beats-052-estimate-sales-855000k-miss-1262m-estimate
Century Therapeutics Q1 2024 GAAP EPS $(0....
05/09/2024 11:58:48

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of ...

piper-sandler-reiterates-overweight-on-century-therapeutics-lowers-price-target-to-9
Piper Sandler Reiterates Overweight on Cen...
04/12/2024 12:43:26

Piper Sandler analyst Edward Tenthoff reiterates Century Therapeutics (NASDAQ:IPSC) with a Overweight and lowers the price t...

small-cap-firm-century-therapeutics-expands-into-autoimmune-diseases-analyst-says-clade-therapeutics-acquisition-intriguing
Small-Cap Firm Century Therapeutics' Expan...
04/11/2024 20:24:12

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including syste...

century-therapeutics-strengthens-its-autoimmune-disease-portfolio-with-pipeline-expansion-supported-by-60m-private-placement-and-acquisition-of-clade-therapeutics
Century Therapeutics Strengthens Its Autoi...
04/11/2024 11:06:21

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond ...

century-therapeutics-presents-new-preclinical-data-highlighting-ipsc-derived-cell-therapy-platform-technology-at-the-2024-aacr-annual-meeting
Century Therapeutics Presents New Preclini...
04/08/2024 20:07:55

Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived...

canaccord-genuity-maintains-buy-on-century-therapeutics-raises-price-target-to-24
Canaccord Genuity Maintains Buy on Century...
03/15/2024 12:14:15

Canaccord Genuity analyst Bill Maughan maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and raises the price target f...

hc-wainwright--co-reiterates-buy-on-century-therapeutics-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Cent...
03/15/2024 10:38:58

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Century Therapeutics (NASDAQ:IPSC) with a Buy and maintains $13 p...

century-therapeutics-q4-earnings-insights
Century Therapeutics: Q4 Earnings Insights
03/14/2024 13:10:05

century-therapeutics-2023-cash-cash-equivalents-and-investments-of-2618m-cash-runway-into-2026
Century Therapeutics' 2023 Cash, Cash Equi...
03/14/2024 11:37:28

century-therapeutics-fy-eps-230-misses-209-estimate-sales-223m-miss-382m-estimate
Century Therapeutics FY EPS $(2.30) Misses...
03/14/2024 11:36:23

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate o...

century-therapeutics-to-present-preclinical-data-from-its-ipsc-derived-cell-therapy-platform-at-the-2024-american-association-for-cancer-research-annual-meeting
Century Therapeutics To Present Preclinica...
03/06/2024 06:27:50

The upcoming abstracts highlight the Company's end-to-end capabilities in iPSC reprogramming and differentiation, gene edit...

russell-2000-rallies-to-16-month-highs-best-performing-small-cap-stocks-popping-over-80-in-december
Russell 2000 Rallies To 16-Month Highs: Be...
12/19/2023 22:05:47

Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 8...

hc-wainwright--co-reiterates-buy-on-century-therapeutics-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Cent...
12/07/2023 11:32:50

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Century Therapeutics (NASDAQ:IPSC) with a Buy and maintains $13 p...

century-therapeutics-receives-fda-clearance-of-ind-application-for-cnty-101-in-systemic-lupus-erythematosus-the-company-plans-to-initiate-phase-1-trial-in-1h-of-2024-initial-data-expected-by-year-end-2024
Century Therapeutics Receives FDA Clearanc...
12/06/2023 12:36:50

century-therapeutics-q3-eps-055-misses-051-estimate-sales-14800k-miss-116m-estimate
Century Therapeutics Q3 EPS $(0.55) Misses...
11/09/2023 12:46:17

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate o...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)